Matrix Metalloproteinase‑1 and MicroRNA‑486‑5p in Urinary Exosomes Can Be Used to Detect Early Lung Cancer: A Preliminary Report

Overview

Journal Oncol Lett

Specialty Oncology

Date 2024 Feb 9

PMID 38333640

Authors

Wataru Ando

Masaya Sogabe

Shigemi Ishikawa

Takayuki Uematsu

Hiroyuki Furuya

Hiroaki Yokomori

Yutaka Kohgo

Katsuya Otori

Tomoyuki Nakano

Shunsuke Endo

Hiroyoshi Tsubochi

Isao Okazaki

Affiliations

Soon will be listed here.

Abstract

The present study describes a novel molecular-genetic method suitable for lung cancer (LC) screening in the work-place and at community health centers. Using urinary-isolated exosomes from 35 patients with LC and 40 healthy volunteers, the expression ratio of MMP-1/CD63, and the relative expression levels of both microRNA (miRNA)-21 and miRNA-486-5p were measured. MMP-1/CD63 expression ratio was significantly higher in patients with LC than in the healthy controls {1.342 [95% confidence interval (CI): 0.890-1.974] vs. 0.600 (0.490-0.900); P<0.0001}. The relative expression of miRNA-486-5p in male healthy controls was significantly different from that in female healthy controls, whereas there was no significant difference in miRNA-21. Receiver operating characteristic curve (ROC) analysis of MMP-1/CD63 showed 92.5% sensitivity and 54.3% specificity, whereas miRNA-486-5p showed 85% sensitivity and 70.8% specificity for men, and 70.0% sensitivity and 72.7% specificity for women. The logistic regression model used to evaluate the association of LC with the combination of MMP-1/CD63 and miRNA-486-5p revealed that the area under the ROC curve was 0.954 (95% CI: 0.908-1.000), and the model had 89% sensitivity and 88% specificity after adjusting for age, sex and smoking status. These data suggested that the combined analysis of MMP-1/CD63 and miRNA-486-5p in urinary exosomes may be used to detect patients with early-stage LC in the work-place and at community health centers, although confirmational studies are warranted.

References

Cazzoli R, Buttitta F, Di Nicola M, Malatesta S, Marchetti A, Rom W . microRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer. J Thorac Oncol. 2013; 8(9):1156-62. PMC: 4123222. DOI: 10.1097/JTO.0b013e318299ac32. View

Shan X, Zhang H, Zhang L, Zhou X, Wang T, Zhang J . Identification of four plasma microRNAs as potential biomarkers in the diagnosis of male lung squamous cell carcinoma patients in China. Cancer Med. 2018; 7(6):2370-2381. PMC: 6010830. DOI: 10.1002/cam4.1490. View

Ando W, Kikuchi K, Uematsu T, Yokomori H, Takaki T, Sogabe M . Novel breast cancer screening: combined expression of miR-21 and MMP-1 in urinary exosomes detects 95% of breast cancer without metastasis. Sci Rep. 2019; 9(1):13595. PMC: 6753125. DOI: 10.1038/s41598-019-50084-5. View

Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I . EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004; 101(36):13306-11. PMC: 516528. DOI: 10.1073/pnas.0405220101. View

Li M, Xiao T, Zhang Y, Feng L, Lin D, Liu Y . Prognostic significance of matrix metalloproteinase-1 levels in peripheral plasma and tumour tissues of lung cancer patients. Lung Cancer. 2010; 69(3):341-7. DOI: 10.1016/j.lungcan.2009.12.007. View

Xu L, Wu Z, Chen Y, Zhu Q, Hamidi S, Navab R . MicroRNA-21 (miR-21) regulates cellular proliferation, invasion, migration, and apoptosis by targeting PTEN, RECK and Bcl-2 in lung squamous carcinoma, Gejiu City, China. PLoS One. 2014; 9(8):e103698. PMC: 4118890. DOI: 10.1371/journal.pone.0103698. View

Okazaki I, Ishikawa S, Ando W, Sohara Y . Lung Adenocarcinoma in Never Smokers: Problems of Primary Prevention from Aspects of Susceptible Genes and Carcinogens. Anticancer Res. 2016; 36(12):6207-6224. DOI: 10.21873/anticanres.11215. View

Rutter J, Mitchell T, Buttice G, Meyers J, Gusella J, Ozelius L . A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res. 1998; 58(23):5321-5. View

Saito R, Miki Y, Ishida N, Inoue C, Kobayashi M, Hata S . The Significance of MMP-1 in EGFR-TKI-Resistant Lung Adenocarcinoma: Potential for Therapeutic Targeting. Int J Mol Sci. 2018; 19(2). PMC: 5855831. DOI: 10.3390/ijms19020609. View

10.

Zhang L, Shan X, Wang J, Zhu J, Huang Z, Zhang H . A three-microRNA signature for lung squamous cell carcinoma diagnosis in Chinese male patients. Oncotarget. 2017; 8(49):86897-86907. PMC: 5689734. DOI: 10.18632/oncotarget.19666. View

11.

Su L, Zhou W, Park S, Wain J, Lynch T, Liu G . Matrix metalloproteinase-1 promoter polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2005; 14(3):567-70. DOI: 10.1158/1055-9965.EPI-04-0482. View

12.

Gavelli G, Giampalma E . Sensitivity and specificity of chest X-ray screening for lung cancer: review article. Cancer. 2001; 89(11 Suppl):2453-6. DOI: 10.1002/1097-0142(20001201)89:11+<2453::aid-cncr21>3.3.co;2-d. View

13.

Schutz A, Roser K, Klitzsch J, Lieder F, Aberger F, Gruber W . Lung Adenocarcinomas and Lung Cancer Cell Lines Show Association of MMP-1 Expression With STAT3 Activation. Transl Oncol. 2015; 8(2):97-105. PMC: 4415137. DOI: 10.1016/j.tranon.2015.02.002. View

14.

An H, Lee Y, Hong S, Kim J, Lee K, Kim Y . The prognostic role of tissue and serum MMP-1 and TIMP-1 expression in patients with non-small cell lung cancer. Pathol Res Pract. 2016; 212(5):357-64. DOI: 10.1016/j.prp.2015.11.014. View

15.

Zhu Y, Spitz M, Lei L, Mills G, Wu X . A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility. Cancer Res. 2001; 61(21):7825-9. View

16.

Feng M, Zhao J, Wang L, Liu J . Upregulated Expression of Serum Exosomal microRNAs as Diagnostic Biomarkers of Lung Adenocarcinoma. Ann Clin Lab Sci. 2019; 48(6):712-718. View

17.

Schutz A, Schneidenbach D, Aust G, Tannapfel A, Steinert M, Wittekind C . Differential expression and activity status of MMP-1, MMP-2 and MMP-9 in tumor and stromal cells of squamous cell carcinomas of the lung. Tumour Biol. 2002; 23(3):179-84. DOI: 10.1159/000064034. View

18.

Elkhouly A, Youness R, Gad M . MicroRNA-486-5p and microRNA-486-3p: Multifaceted pleiotropic mediators in oncological and non-oncological conditions. Noncoding RNA Res. 2020; 5(1):11-21. PMC: 6971376. DOI: 10.1016/j.ncrna.2020.01.001. View

19.

Niland S, Riscanevo A, Eble J . Matrix Metalloproteinases Shape the Tumor Microenvironment in Cancer Progression. Int J Mol Sci. 2022; 23(1). PMC: 8745566. DOI: 10.3390/ijms23010146. View

20.

Matsuzaki K, Fujita K, Jingushi K, Kawashima A, Ujike T, Nagahara A . MiR-21-5p in urinary extracellular vesicles is a novel biomarker of urothelial carcinoma. Oncotarget. 2017; 8(15):24668-24678. PMC: 5421878. DOI: 10.18632/oncotarget.14969. View